Publications: Policy Briefs


La pandemia de COVID-19: el fomento de la I+D y la gestión de la propiedad intelectual para acceder a diagnósticos, medicamentos y vacunas
 Informe Sobre Políticas 73, Mayo 2020

Dr. Viviana Muñoz Tellez
La pandémie de COVID-19 : R&D et gestion de la propriété intellectuelle pour l’accès aux tests diagnostiques, aux médicaments et aux vaccins
 Rapport sur les politiques 73, Mai 2020

Dr. Viviana Muñoz Tellez
Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock
 Policy Brief 75, April 2020

Dr. Germán Velásquez
The COVID-19 Pandemic: R&D and Intellectual Property Management for Access to Diagnostics, Medicines and Vaccines
 Policy Brief 73, April 2020

Dr. Viviana Muñoz Tellez
USMCA debe ser enmendado para asegurar el acceso a medicamentos en México
 Informe Sobre Políticas 64, Agosto de 2019

Maria Fabiana Jorge
The US-Mexico-Canada Agreement: Putting Profits Before Patients
 Policy Brief 61, May 2019

Maria Fabiana Jorge
The ‘obvious to try’ method of addressing strategic patenting: How developing countries can utilise patent law to facilitate access to medicines
 Policy Brief 59, April 2019

Olga Gurgula
Will the Amendment to the TRIPS Agreement Enhance Access to Medicines?
 Policy Brief 57, January 2019

Carlos M. Correa
The Use of TRIPS Flexibilities for the Access to Hepatitis C Treatment
 Policy Brief 54, October 2018

Germán Velásquez
The International Debate on Generic Medicines of Biological Origin
 Policy Brief 50, August 2018

Germán Velásquez
The Need to Avoid “TRIPS-Plus” Patent Clauses in Trade Agreements
 Policy Brief 37, March 2017

Martin Khor
Guidelines on Patentability and Access to Medicines
 Policy Brief 23, October 2015

Germán Velásquez